HKMPY: AI 评分 45/100 — AI 分析 (4月 2026)

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products across various therapeutic areas. The company operates through Injectables, Generics, and Branded segments, serving markets in the United States, the Middle East, North Africa, Europe, and the United Kingdom.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company specializing in generic, branded, and injectable medications across diverse therapeutic areas. With a global presence spanning the US, MENA, and Europe, Hikma leverages its manufacturing capabilities and strategic partnerships to maintain a competitive edge in the specialty and generic drug market.

HKMPY是做什么的？

Founded in 1978 and headquartered in London, Hikma Pharmaceuticals PLC has evolved into a significant player in the global pharmaceutical industry. The company develops, manufactures, and markets a broad portfolio of pharmaceutical products, including generic, branded, and in-licensed medications. Hikma operates through three key segments: Injectables, Generics, and Branded. The Injectables segment focuses on providing generic injectable products primarily for hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment provides branded generics and in-licensed products to retail and hospital markets. Hikma's products cover a wide range of therapeutic areas, including anti-infectives, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. The company has a strong presence in the United States, the Middle East, North Africa, Europe, and the United Kingdom, allowing it to serve diverse patient populations and healthcare systems. Hikma's commitment to quality, innovation, and strategic partnerships has enabled it to maintain a competitive position in the pharmaceutical market.

HKMPY的投资论点是什么？

Hikma Pharmaceuticals presents a compelling investment case based on its diversified revenue streams, strategic market positioning, and commitment to growth. The company’s focus on generic injectables, a high-barrier-to-entry market, provides a stable revenue base. With a P/E ratio of 9.36 and a dividend yield of 4.95%, Hikma offers value and income potential. Growth catalysts include expansion in emerging markets and successful product launches. However, investors should be aware of potential risks, including regulatory changes and competition from other generic manufacturers. Hikma's ability to navigate these challenges will be crucial for sustained growth and profitability.

HKMPY在哪个行业运营？

Hikma Pharmaceuticals operates within the global pharmaceutical industry, which is characterized by increasing demand for generic medications, driven by cost containment measures and patent expirations. The market is highly competitive, with companies like DNPUF (Daiichi Sankyo) and GZPHF (Guangzhou Pharmaceutical) vying for market share. Hikma's focus on specialty generics and injectables allows it to differentiate itself in this competitive landscape. The industry is also subject to stringent regulatory requirements and pricing pressures, requiring companies to maintain operational efficiency and adapt to changing market dynamics.

Drug Manufacturers - Specialty & Generic

Healthcare

HKMPY有哪些增长机遇？

Expansion in Emerging Markets: Hikma has a significant opportunity to expand its presence in emerging markets, particularly in the Middle East and North Africa (MENA) region. These markets are experiencing rapid growth in healthcare spending, driven by increasing populations and rising incomes. By leveraging its existing infrastructure and partnerships, Hikma can capitalize on this growth and increase its market share. This expansion could contribute significantly to revenue growth over the next 3-5 years.
New Product Launches: Hikma's pipeline of generic and branded products represents a significant growth opportunity. Successful launches of new medications can drive revenue growth and increase profitability. The company's focus on specialty generics and injectables, which often have higher barriers to entry, can provide a competitive advantage. Upcoming product launches in key therapeutic areas, such as oncology and cardiovascular disease, are expected to contribute to revenue growth in the near term.
Strategic Acquisitions: Hikma can pursue strategic acquisitions to expand its product portfolio, geographic reach, and manufacturing capabilities. Acquisitions can provide access to new markets, technologies, and expertise, accelerating growth and enhancing competitiveness. The company has a track record of successful acquisitions, and further strategic deals could drive significant value creation in the coming years.
Biosimilar Development: The increasing demand for biosimilars, driven by the expiration of patents on blockbuster biologic drugs, presents a significant growth opportunity for Hikma. Biosimilars offer a lower-cost alternative to branded biologics, and Hikma can leverage its expertise in generic drug development to capitalize on this trend. Investment in biosimilar development and manufacturing capabilities can drive long-term growth and profitability.
Partnerships and Collaborations: Hikma can pursue partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to accelerate innovation, expand its product portfolio, and access new markets. Collaborations can provide access to new technologies, expertise, and distribution channels, enhancing competitiveness and driving growth. Strategic partnerships can also help mitigate risks and reduce development costs.

Market capitalization of $3.70 billion reflects Hikma's established position in the pharmaceutical industry.
Profit margin of 12.0% indicates efficient operations and effective cost management.
Gross margin of 41.4% demonstrates Hikma's ability to maintain profitability despite pricing pressures in the generic drug market.
Beta of 0.65 suggests lower volatility compared to the overall market, potentially offering stability in investment portfolios.
Dividend yield of 4.95% provides an attractive income stream for investors.

HKMPY提供哪些产品和服务？

Develops and manufactures generic pharmaceutical products.
Markets and sells branded pharmaceutical products.
Offers injectable medications primarily for hospital use.
Provides oral and non-injectable generic products for retail markets.
In-licenses pharmaceutical products for distribution.
Operates in various therapeutic areas, including cardiovascular, oncology, and diabetes.
Serves markets in the United States, Middle East, North Africa, Europe, and the United Kingdom.

HKMPY如何赚钱？

Develops and manufactures generic and branded pharmaceutical products.
Markets and sells products through three segments: Injectables, Generics, and Branded.
Generates revenue through sales of pharmaceutical products to hospitals, retail pharmacies, and other healthcare providers.

Hospitals and healthcare facilities (for injectable medications).
Retail pharmacies (for oral and non-injectable generic products).
Patients (through prescriptions and over-the-counter medications).
Wholesalers and distributors (who supply medications to pharmacies and hospitals).

Manufacturing capabilities: Hikma has established manufacturing facilities that allow it to produce a wide range of pharmaceutical products.
Established distribution network: The company has a strong distribution network in key markets, including the United States, the Middle East, and North Africa.
Product portfolio: Hikma offers a diversified portfolio of generic, branded, and in-licensed pharmaceutical products.
Regulatory expertise: The company has experience navigating complex regulatory requirements in various markets.

什么因素可能推动HKMPY股价上涨？

Upcoming: Potential for new product approvals and launches in key therapeutic areas.
Ongoing: Expansion in emerging markets, particularly in the MENA region.
Ongoing: Strategic acquisitions and partnerships to expand product portfolio and geographic reach.

HKMPY的主要风险是什么？

Potential: Pricing pressures in the generic drug market.
Potential: Regulatory changes and compliance issues.
Ongoing: Competition from other generic drug manufacturers.
Potential: Currency fluctuations and economic downturns.

HKMPY的核心优势是什么？

Diversified product portfolio across generics, injectables, and branded products.
Strong presence in key markets, including the United States, the Middle East, and North Africa.
Established manufacturing capabilities and distribution network.
Experienced management team with a track record of successful acquisitions.

HKMPY的劣势是什么？

Exposure to pricing pressures in the generic drug market.
Dependence on key products and markets.
Potential for regulatory challenges and compliance issues.
Limited investment in innovative research and development.

HKMPY有哪些机遇？

Expansion in emerging markets with growing healthcare spending.
New product launches and pipeline development.
Strategic acquisitions and partnerships.
Increasing demand for biosimilars.

HKMPY面临哪些威胁？

Competition from other generic drug manufacturers.
Patent expirations and loss of exclusivity.
Changes in healthcare regulations and reimbursement policies.
Economic downturns and currency fluctuations.

HKMPY的竞争对手是谁？

Daiichi Sankyo — Focuses on innovative pharmaceuticals and oncology. — (DNPUF)
Guangzhou Pharmaceutical — A major pharmaceutical company in China. — (GZPHF)
Haleon PLC — Focuses on consumer healthcare products. — (HLBBF)
Hillebrand Group AG — Provides logistics services for the beverage industry. — (HLUBF)
Luzhou Laojiao Co Ltd — Chinese distiller — (LVZPF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Said Samih Taleb Darwazah
Headquarters: London, GB
Employees: 9,500
Founded: 2012

AI Insight

AI analysis pending for HKMPY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: HKMP

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Hikma Pharmaceuticals PLC do?

Hikma Pharmaceuticals PLC is a global pharmaceutical company that develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. Its products cover various therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, and respiratory. Hikma serves markets in the United States, the Middle East, North Africa, Europe, and the United Kingdom, providing essential medications to patients and healthcare providers.

What do analysts say about HKMPY stock?

Analyst coverage of HKMPY is pending, but based on available financial data, Hikma Pharmaceuticals PLC has a market capitalization of $3.70 billion and a P/E ratio of 9.36. The company's profit margin is 12.0%, and its gross margin is 41.4%. These metrics suggest that Hikma is a profitable and well-managed company. these may be worth researching factors, as well as the company's growth prospects and risk factors, when evaluating HKMPY stock.

What are the main risks for HKMPY?

Hikma Pharmaceuticals PLC faces several risks, including pricing pressures in the generic drug market, competition from other generic drug manufacturers, regulatory changes and compliance issues, and currency fluctuations. The company's dependence on key products and markets also poses a risk. Investors should carefully consider these risks before investing in HKMPY stock. Hikma's ability to mitigate these risks will be crucial for sustained growth and profitability.